ArticleJournal of Taibah University Medical Sciences2026
Oxidative DNA damage level and lipid peroxidation status in subclinical hypothyroid patients compared with euthyroid individuals.
Article in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study focused on measuring oxidative DNA damage and oxidative stress biomarkers in subclinical hypothyroidism (SCH) patients to gain insight on the condition's contribution to metabolic consequences. Additionally, it assesses the impact of levothyroxine replacement therapy on oxidative stress and DNA damage in patients with SCH over a specified duration of treatment. Methods: A case-control study was done at the Diabetes and Endocrine Center, Azadi Teaching Hospital, Duhok, Kurdistan Region, Iraq, from June 2024 to February 2025. The participants were divided into four groups: euthyroid controls (G1, n = 80), previously treated SCH (G2, n = 44), newly diagnosed SCH (G3, n = 105), and newly diagnosed SCH patients on follow-up levothyroxine therapy (LT4) (G4, n = 20). Oxidative stress and oxidative DNA damage biomarkers were assessed and compared in all study groups. Results: The research comprised 249 participants: 169 with SCH and 80 euthyroid controls. Compared to G1, oxidized low-density lipoprotein (ox-LDL) and total oxidant status (TOS) were higher in groups G2, G3, and G4 ( Conclusion: SCH patients, especially newly diagnosed, show elevated oxidative stress, DNA damage, and reduced antioxidant capacity versus euthyroid controls, elucidating metabolic complications and validating oxidative biomarkers for early risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.